Rani Therapeutics Holdings, Inc.
Rani Therapeutics Holdings, Inc. (RANI) Stock Forecast & Analyst Price Target
Wall Street consensus, 12-month price targets, model projections, and EPS/revenue estimates — from analyst data and price history.
rani · stock forecast · 7 analysts (3M) · FMP · updated Jun 9, 2026
Analyst Rating & Consensus
Based on 7 Wall Street analysts in the past 3 months
Buy
7 analysts
consensus
Rating Breakdown
12-Month Price Target
High
$28.00
Consensus
$15.67
+1766.4% upside
Low
$9.00
Median: $10 · Last Close: $0.84
12-Month Price Target Forecast
Historical closing prices + analyst 12-month price target forecast cone
Short-Term Price Prediction
Low ActivityAlgorithmically generated · Updated daily
| Date | Predicted Price | Change |
|---|---|---|
| 2026-06-10 | $0.80 | ↓ 5.00% |
1-day model range: $0.77–$0.82. Peak: $0.82 (-5.00%).
Long-Term Stock Price Prediction
Stock Forecast Based on Technical Analysis
14 TA signals (SMA×6 + EMA×6 + RSI + MACD) · EEAT method transparency
Insufficient Trading Activity — Sentiment Signals Disabled
This stock has very low trading volume (ZOMBIE condition). Sentiment analysis requires sufficient price action. RSI and MACD values below are still shown for reference.
Moving Averages · RANI · Jun 9, 2026
Latest Analyst Ratings & Upgrades
| Date | Brokerage | Action | Rating |
|---|---|---|---|
| 2026-05-20 | Canaccord Genuity | Maintains | Buy→Buy |
| 2026-04-01 | Canaccord Genuity | Maintains | Buy→Buy |
| 2026-03-27 | HC Wainwright & Co. | Maintains | Buy→Buy |
| 2026-01-09 | HC Wainwright & Co. | Maintains | Buy→Buy |
| 2025-10-20 | Maxim Group | Maintains | Buy→Buy |
| 2025-05-16 | Oppenheimer | Maintains | Outperform→Outperform |
| 2025-04-03 | HC Wainwright & Co. | Maintains | Buy→Buy |
| 2025-02-26 | Canaccord Genuity | Maintains | Buy→Buy |
| 2025-02-07 | HC Wainwright & Co. | Maintains | Buy→Buy |
| 2024-11-19 | HC Wainwright & Co. | Maintains | Buy→Buy |
Wall Street analysts have recently issued updated ratings on Rani Therapeutics Holdings, Inc. (RANI) stock. Of the recent 26 rating actions, 0 were upgrades and 0 were downgrades. 7 analysts currently cover RANI.
Analyst Recommendation Trends
RANI analyst recommendation trends show stable buy-side sentiment over the past 6 months. Buy rating actions changed from 1 to 1 per month.
Financial Forecast: EPS & Revenue Estimates
Revenue This Year
$4M
↓ 74.6% YoY
Revenue Next Year
$5M
↑ 19.4% YoY
EPS This Year
$-0.19
EPS Next Year
$-0.21
↑ 11.7% YoY
EPS ForecastReported vs Estimated
Analysts forecast RANI EPS of $-0.19 for the current fiscal year, based on estimates from 2 analysts. The RANI revenue forecast is $4M for the current year. These are analyst consensus estimates via FMP / S&P Global.
About Forecast & Price Prediction
The RANI stock forecast is supported by two independent data sources: analyst consensus ratings from 7 Wall Street analysts (S&P Global / FMP), and technical analysis calculated from historical EOD price data. The consensus RANI price target is $15.67 (+1766.4% upside), with an analyst consensus of Buy.
The RANI short-term stock prediction for tomorrow is $0.80 (-5.00%).
Rani Therapeutics Holdings, Inc. trades on NASDAQ under the ticker RANI. The RANI stock outlook for 2027 is broadly positive, supported by a Buy consensus among 100% of covering analysts.
Frequently asked questions
RANI forecast · 8 questionsAccording to 7 Wall Street analysts, the average 12-month RANI price target is $15.67, with a high forecast of $28.00 and a low of $9.00. The median price target is shown in the chart above when available. This implies +1766.4% potential upside from the current price of $0.84.
· Analyst data: Financial Modeling Prep (FMP) · S&P Global Market Intelligence · Technical analysis: FMP /historical-price-eod/light · Updated: Hourly (analyst) · Daily (technical)
⚠ This information is provided for informational purposes only and does not constitute investment advice. Short-term and long-term price predictions are algorithmically generated and carry significant uncertainty. Past performance does not guarantee future results. Always conduct your own due diligence before making investment decisions.